Karen Rodriguez Lorenc has overseen linvoseltamab's development and subsequent approval in Europe, now waiting for its US fate, she talked to In Vivo about how patient-centric drug development philosophy is core to her leadership, and why she doesn't believe in failure.

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.

UK biotech targets the root cause of metabolic disease while preserving muscle mass in a crowded obesity market.

As president of US Hematology at J&J, June Lanoue's leadership approach focuses on improving patient outcomes and organizational development. Her career path demonstrates the role of curiosity and adaptability in health care advancement.

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy